Results 241 to 250 of about 129,345 (287)
Psilocybin as a novel treatment for chronic pain
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Prioritising research on endocrine disruption in the marine environment: a global perspective
ABSTRACT A healthy ocean is a crucial life support system that regulates the global climate, is a source of oxygen and supports major economic activities. A vast and understudied biodiversity from micro‐ to macro‐organisms is integral to ocean health.
Patricia I. S. Pinto +23 more
wiley +1 more source
FAM20C regulates the composition of the YTHDC1‐NCL‐KAP1‐LINE1 RNAs complex, thereby affecting neuronal differentiation in hypoxic–ischemic brain damage (HIBD). ABSTRACT Neurodevelopmental impairment due to hypoxic–ischemic brain damage (HIBD) lacks effective biomarkers and therapeutic targets.
Chen‐xi Feng +8 more
wiley +1 more source
Myeloid PD‐1 Regulates Astrocyte Development and Leads to Active Behaviours
During early neurodevelopment, PD‐1 ablation in myeloid cells influences myeloid proliferation/differentiation and causes sustained astrocyte overproliferation. PD‐1f/f; LysM‐Cre mice showed elevated astrocyte gene expression and behavioural changes.
Jie Qin +6 more
wiley +1 more source
Following TBI, hippocampal neurogenesis in mice is impaired and affects cognitive function. This impairment is associated with the upregulation of p‐AKT/AKT mediated by ROCK1. ABSTRACT Traumatic brain injury (TBI) represents a global health burden, often resulting in persistent neurological deficits due to impaired hippocampal neurogenesis ...
Chaoqun Yao +15 more
wiley +1 more source

